固定设计在研随机对照试验中方案变更的合法与不合法之分
该研究基于一项他汀类药物二级预防大型试验的数据,构造零假设与备择假设下的模拟试验数据集,比较知晓治疗分配后变更设计或分析(不合法)与不知晓治疗分配下变更(合法)的表现。不合法变更在备择假设下产生61%的相对偏倚,在零假设下1类错误率达23%,远超5%显著性水平;合法变更则无偏且不膨胀1类错误率。结论提示在研固定设计RCT的方案变更需警惕因知晓分配而引入偏倚,合法变更应充分记录。
要点
- 知晓治疗分配后变更设计或分析属不合法,可致显著偏倚与1类错误膨胀。
- 不知晓治疗分配下进行的合法变更不引入偏倚,也不膨胀1类错误率。
- 合法变更需充分记录,以向各利益相关方保证其有效性。
核心结论
- 在研固定设计RCT的方案变更若在知晓治疗分配下进行,会引入偏倚并膨胀1类错误率;不知晓分配下的合法变更则无此风险,且需充分记录。
研究设计与样本
- 基于一项他汀类药物二级预防大型试验数据,生成零假设与备择假设下的模拟试验数据集,比较合法与不合法变更策略的表现。
- 以1类错误率及治疗效应的绝对与相对偏倚作为评价指标。
主要发现
- 不合法变更在备择假设下产生61%的相对偏倚,在零假设下1类错误率为23%,远超5%显著性水平。
- 合法变更在备择假设下产生无偏估计,且未膨胀零假设下的1类错误率。
临床怎么用
- 对在研固定设计RCT进行方案变更时,应避免基于治疗分配信息决策,并对合法变更充分记录以保障其有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite careful planning, changes to some aspects of an ongoing randomised clinical trial (RCT), with a fixed design, may be warranted. We sought to elucidate the distinction between legitimate versus illegitimate changes to serve as a guide for less experienced clinical trialists and other stakeholders. METHODS: Using data from a large trial of statin therapy for secondary prevention, we generated a set of simulated trial datasets under the null hypothesis (H0) and a set under an alternative hypothesis (H1). Through analysis of these simulated trials, we assessed the performance of the strategy of changing aspects of the design/analysis with knowledge of treatment allocation (illegitimate) versus the strategy of making changes without knowledge of treatment allocation (legitimate). Performance was assessed using the type 1 error, as well as measures of absolute and relative bias in the treatment effect. RESULTS: Illegitimate changes led to a relative bias of 61% under H1, and a type 1 error rate under H0 of 23%-well in excess of the 5% significance level targeted. Legitimate changes produced unbiased estimates under H1 and did not inflate the type 1 error rate under H0. CONCLUSIONS: Changes to pre-specified aspects of the design and analysis of an ongoing RCT may be a necessary response to unforeseen circumstances. Such changes risk introducing a bias if undertaken with knowledge of treatment allocation. Legitimate changes need to be adequately documented to provide assurance to all stakeholders of their validity.
引用
- Coskinas X, Simes J, Schou M, et al. Changes to aspects of ongoing randomised controlled trials with fixed designs. Trials. 2020. PMID: 32493444. doi:10.1186/s13063-020-04374-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。